News

Compared to other molecules currently in development in the immune therapy cancer space, AUNP-12 provides a breakthrough mechanism of action in the PD-1 pathway. AUNP-12 is the only

Synribo, an oncology portfolio product, was originally granted an accelerated approval by the FDA in October 2012. Additional clinical trial data was required to fulfill post marketing requirements

Abilify Maintena will be the first commercialized product in Canada from the global Otsuka- Lundbeck alliance, which is focused on developing Central Nervous System (CNS) therapies worldwide. The

The launch will feature three products: Rabecure Pack 400 and Rabecure Pack 800, which package together individual blister sheets each containing a daily triple formulation dose of Pariet,

This synovial analysis, suggested by the FDA, tests the change in expression of signaling and structural proteins that arise from the treatment of the knee with either Ampion

The results of Study 801 from the Phase III clinical study demonstrate that extended-release hydrocodone was well tolerated and effective for the treatment of moderate-to-severe chronic low back

Bayer is licensing an early-stage drug discovery program directed against an epigenetic drug target. Inhibiting epigenetic targets is widely recognized as a promising emerging therapeutic option for cancer

The three parties have entered into a binding agreement wherein Alexion has an exclusive option to acquire privately-held Prothelia and license Laminin-111 directly from the University of Nevada,

The company is utilizing its ProNutrein discovery platform to identify and develop protein pharmaconutrients, protein nutrients identified in food with beneficial impact in many areas of human health,